207 Exploring the experiences of rural and coastal people with lung cancer and their informal carers' in accessing and engaging in treatment: A qualitative interview study
There are wide variations and inequalities in lung cancer care across the UK, but most research has focused on improving the quality of clinical services and less on individual-related factors. There is evidence to suggest that rural people with lung cancer may experience unique inequalities in care compared to their urban counterparts. Lincolnshire has some of the most deprived parts of the UK, particularly in rural and coastal areas, where people face considerable barriers to engaging with, and accessing cancer care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Samuel Cooke, Lucy Mitchinson, Daisy McInnerney, Samantha L Quaife, Zara Pogson, Dawn Skinner, Sarah Civello, Ava Harding-Bell, Ros Kane, Lynn Calman, Peter Selby, Adam Januszewski, Maria Lapuente, Annie Reeves, William Ricketts, Brian Knowles, Michael D Tags: Trials in progress Source Type: research
208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma
Mesothelioma is a rare cancer caused by exposure to asbestos typically affecting the pleura or pericardium. Prognosis remains dismal yet targeted therapies are lacking. Advances have revealed a preponderance of tumour suppressors in mesothelioma, which may present new opportunities to develop treatments. The SELECTmeso trial platform, coordinated by the Cancer Research UK Southampton Clinical Trials Unit, has been developed to leverage new insights into synthetic lethal biology to improve treatment outcomes. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Kayleigh Hill, Dean Fennell, Anna Song, Robin Wickens, Judith Cave, Andrea Corkhill, Jens Hahne, Michelle Lattimore, Peter Wells-Jordan, Nada Nusrat, Sean Dulloo, Charlotte Poile, Gareth Griffiths Tags: Trials in progress Source Type: research
209 ThOracic Umbrella RadIotherapy STudy in stage IV NSCLC: TOURIST
Palliative radiotherapy is widely used in stage IV non-small cell lung cancer (NSCLC). Radiotherapy dose fractionation studies have shown its utility in symptom control with improved survival at higher doses. Recent advances in radiotherapy planning and delivery offer dose escalation while reducing toxicity. However, there are no studies testing palliative radiotherapy in combination with modern systemic therapies and trials are needed to test timing, dose and fractionation in that context. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: David Woolf, Nichola Downs, Chris Sutton, Andrea Corkhill, Izabella Eberhart, Siva Saranya, Kayleigh Hill, Sean Ewings, Gabriel Rogers, Lynn Calman, Amy Hancock, Merina Ahmed, Janette Rawlinson, Jacqui Gath, Caroline Lee, Crispin Hiley, Gareth Griffiths, Tags: Trials in progress Source Type: research
210 If at first you don't succeed …switching treatments in NTRK fusion NSCLC
We describe a young patient treated with NTRK inhibitors with a remarkable response, albeit requiring a drug switch due to severe hepatotoxicity. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Deborah Scott, Tom Geldart Tags: Case Reports Source Type: research
211 The impact of the flu vaccine on fluid volumes in a patient with mesothelioma
A 78-year-old woman with end stage chronic obstructive pulmonary disease and a right pleural mesothelioma had an indwelling pleural catheter (IPC) in situ for control of her malignant effusion. She was for best supportive care. Serous, yellow fluid was drained 2 –3 times a week, volumes averaged 150–200 mls. The patient underwent influenza vaccination as part of yearly routine primary care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Leah Taylor, Helen Wallace, Avinash Aujayeb Tags: Case Reports Source Type: research
212 Incidence and Outcomes of MRI-confirmed Myocarditis in Patients Receiving Immune Checkpoint Inhibitors for Lung Cancer - A Single Tertiary Centre Experience
Myocarditis is a rare and life-threatening complication of immune checkpoint inhibitors (ICI). Lung cancer patients present a diagnostic conundrum with overlapping symptoms, co-morbidities, treatment toxicity, and tumour burden. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Alfred So, Arjun K Ghosh, Charlotte Manisty, Adam Januszweski Tags: Case Reports Source Type: research
213 Selpercatinib in RET Fusion Lung Adenocarcinoma
We present our early experience with KIF5B:RET fusion LAC treated with Selpercatinib. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Ramesh Bulusu, Sherin Paul, Sherin Paul, Nicholas Brown, Geethu Punnen, Anil Kumar Geetha, Timothy Chapman Tags: Case Reports Source Type: research
214 Rowell Syndrome as a Paraneoplastic Manifestation of Metastatic Mesothelioma
A 60-year-old male presented in 2021 with pulmonary metastatic epitheloid mesothelioma. Notable history included psoriasis and T4aN2bM0 sarcomatoid squamous-cell-carcinoma of the oral-cavity treated with palliative radiotherapy. Due to an extraordinary response to radiotherapy, Head and Neck Multidisciplinary-Team-Meeting re-review felt a lymphomatoid process more likely. For mesothelioma, he completed 4 cycles of palliative pemetrexed/ carboplatin chemotherapy with partial-response but then stopped due to bone-marrow toxicity. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Helen-Cara Younan, Eunice Xing, Hend Owaidat, Polyanna Leite, Danielle Power, Waleed Mohammed, Joanne Evans Tags: Case Reports Source Type: research
215 Metastatic NSCLC adenocarcinoma with extremely rare EGFR exon 21 p. (Leu833_His835delinsValValLeu) mutation is clinically sensitive to Osimertinib
We present the case of an individual with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma with an extremely rare epidermal growth factor receptor (EGFR) exon 21 p. (Leu833_His835delinsValValLeu) mutation who has had a sustained clinical response to osimertinib for almost 3 years. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Shawn Ellis, Jocelyn Adams, Rebecca Johnson, Philip Bennett Tags: Case Reports Source Type: research
216 Prolonged Localised Inflammatory Response following Bronchoscopic Thermal Vapour Ablation Therapy mimicking Lung Cancer
Bronchoscopic thermal vapour ablation (BTVA) is a bronchoscopic lung volume reduction technique considered in patients with emphysema and hyperinflation. BTVA uses steam to induce a localised inflammatory response (LIR) within the target lobe and subsequent fibrosis and atelectasis creates lung volume reduction. The area of LIR can cause symptoms and radiographic features indistinguishable from pneumonia with the reaction peaking in the first 2 –4 weeks and usually resolving within 8–12 weeks [1]. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Phil Reid, Lewis Bain Tags: Case Reports Source Type: research
217 Atypical pseudoprogression in non-small cell lung cancer treated with pembrolizumab.
Pseudoprogression is a phenomenon associated with immune checkpoint inhibitors (ICIs). It is defined radiologically as an initial increase in tumour size or new lesions, followed by a decrease in tumour burden. Delayed pseudoprogression, seen after an initial response to ICI, is more rarely seen. Whilst rare cases of delayed pseudoprogression in lung cancer have previously been reported, delayed pseudoprogression followed by prolonged stable disease in the absence of further treatment has not been previously documented. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Aman Singh, Sarah Cotter, Amy Ford, Alasdair Taylor Tags: Case Reports Source Type: research
218 A case of Toxic Epidermal Necrolysis secondary to combination Ipilimumab and Nivolumab therapy for Pleural Mesothelioma, successfully treated with Ruxolitinib
We present the case of a patient who developed Toxic Epidermal Necrolysis (TEN) as the primary feature of a multi-system autoimmune syndrome following combination ipilimumab and nivolumab for mesothelioma, successfully treated with Ruxolitinib. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Judy Tabbakh, Racha Kussaibati, Francesca Kinsella, Gary Middleton, Victoria Kunene, Sawsan Elsheikh, Claudia Roberts, Darren Lewis, Rachel Powell, Ser-Ling Chua, Shobhit Baijal Tags: Case Reports Source Type: research
219 Oesophageal EUS-guided Pericardiocentesis: A Therapeutic Conundrum in Patient with EGFR-positive Metastatic Lung Adenocarcinoma and Posterior Pericardial Tamponade
Treatment for malignant loculated pericardial effusions are limited and they often reaccumulate following surgical management. Here we report a case of oesophageal endoscopic ultrasound (EUS) guided pericardiocentesis for a loculated posterior malignant pericardial effusion causing haemodynamic compromise. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Alfred So, John Conibear, Adam Januszweski, Charlotte Manisty, William Ricketts, David Waller, Patrick Wilson, Kelvin Lau Tags: Case Reports Source Type: research
220 Patient with T1N3M1 (liver) non-squamous NSCLC diagnosed July 2008. Subsequently confirmed EXON 18 EGFR mutation (2016) - Durable Survival, Late Effects: Learning from our patient's experiences over a 16 year period (2008 to the present)
We wish to share the multiple learning points from the experience of our patient MP – whom CR and PMM first met in 2008 and remaining colleagues met in the subsequent decade and a half. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Paula Mulvenna, Matthew Anderson, Margaret Peel, Christine Ruahton, Sally Hall, Jill Gardiner, Greystoke Alastair, Damian Holliman, Priya Bhatnagar Tags: Case Reports Source Type: research
Contents
(Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Source Type: research
